| Online-Ressource |
Verfasst von: | Keßler, Torsten [VerfasserIn]  |
| Müller-Tidow, Carsten [VerfasserIn]  |
Titel: | Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML) |
Verf.angabe: | Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, Martina Crysandt, Jan-Henrik Mikesch, Saskia von Stillfried, Matthias Stelljes, Michele Pohlen, Georg Lenz, Anna Kirsch, Kerstin Vehring, Eva Wardelmann, Wolfgang Hartmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, Carsten Müller-Tidow, Wolfgang E. Berdel |
E-Jahr: | 2019 |
Jahr: | 21 March 2019 |
Umfang: | 9 S. |
Fussnoten: | Gesehen am 14.06.2019 |
Titel Quelle: | Enthalten in: Annals of hematology |
Ort Quelle: | Berlin : Springer, 1955 |
Jahr Quelle: | 2019 |
Band/Heft Quelle: | 98(2019), 6, Seite 1393-1401 |
ISSN Quelle: | 1432-0584 |
Abstract: | We evaluated pazopanib (800 mg orally QD) in patients not eligible for intensive treatment with relapsed/refractory AML or at initial diagnosis. Patients receiving pazopanib for > 14 days were analyzed for safety, tolerability, and efficacy. Co-primary endpoints were cumulative response rate and reduction of bone marrow microvessel density. Twenty patients (median age 76 years, range 52-86) were treated. Fifteen had relapsed/refractory and five had newly diagnosed AML. Median ECOG performance status was 1 (range 1-3). Four patients had adverse, 15 intermediate, and 1 patient favorable cytogenetic/molecular risk (ELN 2010 criteria). The safety profile of pazopanib was as reported. The most common adverse events of any grade were gastrointestinal. Two patients achieved PR (blast reduction > 50%), 14 stable disease (SD), and 4 progressive disease. Median PFS was 65 days (95% CI 29-105). After the end of the study, 1 CRi and 1 CRp occurred on demethylating agents, and 1 CR upon alloSCT. In these patients, SD and improved general condition on pazopanib allowed therapy escalation. Median OS for the overall study population was 191 days (95% CI 87-435) and 1-year survival was 35%. There was no significant change in microvessel density. Clinical trial information: NCT01361334. |
DOI: | doi:10.1007/s00277-019-03651-9 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1007/s00277-019-03651-9 |
| DOI: https://doi.org/10.1007/s00277-019-03651-9 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Acute myeloid leukemia |
| AML |
| Pazopanib |
| Phase II study |
K10plus-PPN: | 1667485679 |
Verknüpfungen: | → Zeitschrift |
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML) / Keßler, Torsten [VerfasserIn]; 21 March 2019 (Online-Ressource)